Edition:
India

People: Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

87.14USD
8:46pm IST
Change (% chg)

$-2.05 (-2.29%)
Prev Close
$89.19
Open
$89.49
Day's High
$89.49
Day's Low
$85.79
Volume
20,165
Avg. Vol
91,861
52-wk High
$127.74
52-wk Low
$64.25

Luly, Jay 

Dr. Jay R. Luly, Ph.D. is President, Chief Executive Officer, Director of the company. Luly has served as our President and Chief Executive Officer and as a member of our board of directors since July 2003. Prior to joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. Before joining Oxford in March 2002, Dr. Luly held the positions of Senior Vice President, Research and Development Operations and Senior Vice President, Discovery Strategy and Operations at Millennium Pharmaceuticals following Millennium’s merger with LeukoSite, Inc., where he had served as Senior Vice President, Drug Discovery and Preclinical Development. Prior to joining LeukoSite, he held a number of senior drug discovery positions at Abbott Laboratories from 1983 to 1997. Dr. Luly received a B.S. from the University of Illinois, Urbana/Champaign and a Ph.D. in synthetic organic chemistry from the University of California, Berkeley.

Basic Compensation

Total Annual Compensation, USD 611,178
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 3,897,560
Fiscal Year Total, USD 4,508,740

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 8,498 715,818.00
Name Fiscal Year Total

Bruce Carter

394,190

Jay Luly

4,508,740

Paul Mellett

1,421,280

Yat Sun Or

1,524,000

Nathaniel Gardiner

1,376,110

Nathalie Adda

1,514,080
As Of  30 Sep 2018